Belgium takes a key role in European initiative to boost African Vaccine Manufacturing

health worker preparing a vaccine

MAV+ (Manufacturing and Access to Vaccines, Medicines and Health Technology Products in Africa) is a European initiative that saw the light in the wake of the corona pandemic, and in which Belgium has taken a leading role through its expertise and bilateral, non-governmental and multilateral funding.

MAV+ is to promote production of and access to vaccines, medicines and health technologies in Africa. In collaboration with the African Union and the European Union, it aims to increase African vaccine production to 60% of Africa’s vaccine needs by 2040.

After negotiations between the administration, Germany, France and the European Commission, the technical implementation of the initiative was entrusted to a consortium of three European agencies: Enabel, Expertise France and GIZ. Enabel ensures the coordination.

The activities aim to guide the EU, Member States, the African Centre for Disease Prevention and Control (Africa CDC) and the African Partnership for Vaccine Production (PAVM) on pharmaceutical regulation, technology transfer and intellectual property, industrial development and cooperation with the private sector, as well as research and capacity development. Among other things, this should lead to national regulatory instances eventually attaining a level of quality (‘maturity level 3’ in World Health Organisation terminology) allowing them to decide on market access for vaccines produced in Africa. To this end, collaboration in Belgium is ensured with Sciensano, the Federal Agency for Medicines and Health Products (FAMHP) and QUAMED (Quality Medicine for All).

Other activities include the material equipment of laboratories, the digitalisation of the operation of African agencies, and the establishment of a master’s degree in biotechnology at the University of Rwanda in cooperation with the Université Libre de Bruxelles (ULB).

Thanks to complementary parallel Belgian funding to the European initiative, Enabel will also support the African Medicines Agency (AMA) and the equitable access to quality health products in Africa. The coordination team, comprising about 10 people from Enabel, Expertise France and GIZ, is based in Enabel’s offices.

More updates and resources

kid jumping on a stage News

08 June 2024

Investing in the future: 2023 – 2024 Activity report

Find out why we have to upcycle international cooperation. Why Enabel is not only a Belgian, but also a European and African agency. Find out about the starting of activities in a new country: Ukraine. About the launch of activities in the green hydrogen sector.

Read more

women and a man working on a laptop News

07 June 2024

Pioneering innovative development

Enabel is a steadfast innovation partner, committed to supporting creative entrepreneurs and courageous intrapreneurs, across the globe, across sectors.

Read more

women selecting coffee grounds News

07 June 2024

Decent work for better social protection

Job creation, workers' rights, social protection and social dialogue: in the Great Lakes region, we are implementing a series of projects dedicated exclusively to achieving these objectives.

Read more

Man working in a hospital laboratory News

07 June 2024

Modernise, train, care

Health is a key sector in Enabel's cooperation with Burundi, leading to significant improvements in medical infrastructure, digitized health services, staff training, and other essential initiatives over the past decade.

Read more

square in Kyiv, Ukraine News

07 June 2024

Ukraine: new country, new challenges

In December 2023, the Belgian government mandated our organisation to launch a programme in support of reconstruction in Ukraine.

Read more

News

07 June 2024

Growth? Yes, inclusive growth

Growth doesn't always benefit everyone. That's why we aim for 'inclusive growth,' ensuring participation of women, young people and vulnerable groups. This is how.

Read more

Stay informed

Keep up-to-date with our latest activities and international development trends from a Belgian perspective.

Newsletter

"*" indicates required fields